The use of Immune Globulin (Human) in the modification of measles has been known for a considerable period. McKhann and Chu1 gave doses of from 5 to 6 cc. to forty-two children who were exposed to the disease. Of this number, thirty-seven were completely protected and in five mild modified measles developed. Whether the child was protected or modified measles developed depended on the number of days of incubation that had elapsed prior to injection of the extract. These cases were all in an institution. There has been little in the literature concerning the treatment of fully developed measles through the use of Immune Globulin (Human). It is part of my purpose in this paper to show the very definite therapeutic value of Immune Globulin (Human) in treatment of well developed cases of measles.
MODE OF PREPARATION AND STANDARDIZATION OF IMMUNE GLOBULIN (HUMAN)
The preparation used in these cases
LEVITAS IM. TREATMENT, MODIFICATION AND PREVENTION OF MEASLES BY USE OF IMMUNE GLOBULIN (HUMAN). JAMA. 1935;105(7):493–496. doi:10.1001/jama.1935.02760330019005
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: